Earnings Releases·Nov 5, 2026, 4:07 PM ET

Solventum — Third Quarter 2026 Earnings Summary

Reported Q3 net sales of $1.9 billion (down 7.0% YoY, down 2.8% organic) and adjusted diluted EPS of $1.45 (down 3.6% YoY), while nine-month adjusted EPS rose 20.9% to $5.48.
Raised full-year adjusted EPS guidance to $7.20–$7.30 and affirmed free cash flow guidance of $200–$300 million, with expectations to accelerate sales growth and expand margins.
Completed ERP system cutover during the quarter and exited approximately 90% of 3M transition service agreements, though Q3 organic sales were impacted by a 630 basis point reversal of advance orders.
Purchased $403 million in treasury stock over the nine months; the company is reviewing strategic alternatives for the Health Information Systems business.